NCT07337772 Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty
| NCT ID | NCT07337772 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Adrenal Cortex Hormones |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2028-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-02-01 with a primary completion date of 2028-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the efficacy of different doses of glucocorticoids in local infiltration analgesia (LIA) during total knee arthroplasty (TKA) through a prospective single-center randomized controlled trial, and to explore the safety and feasibility of high-dose glucocorticoids. Through this research, the investigators hope to provide an optimized solution for post-TKA pain management, improve patients' postoperative recovery and quality of life, and offer scientific evidence for pain management following TKA.
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants aged 18 years or older; 2. Undergoing primary unilateral total knee arthroplasty (TKA)for unilateral knee osteoarthritis(OA)at ourhospital; 3. Preoperative American Society of Anesthesiologists(ASA)physical status classification of 1-3; 4. Ability to provide informed consent and sign a written informed consent form. Exclusion Criteria: 1. Previous surgery on the operative knee or a history of infection in the operative knee; 2. Non-osteoarthritis conditions (including rheumatoid arthritis, traumatic arthritis, septic arthritis, and hemophilic arthritis); 3. Severe osteoarthritis (including flexion contracture \>30° or varus/valgus deformity \>30°); 4. Allergy to the relevant study drugs; 5. Presence of neuromuscular dysfunction in the ipsilateral limb; 6. Dependence on anesthetic drugs (defined as weekly use of opioids exceeding 100 mg morphine equivalents or local anesthetics for preoperative pain control for more than 3 months); 7. Poor systemic condition, including but not limited to: glycated hemoglobin (HbA1c) level \>12%; blood pressure \>170/110 mmHg (1 mmHg = 0.133 kPa); history of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure, or any acute coronary event within 6 months; dialysis or renal transplantation; pregnancy or lactation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07337772 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Adrenal Cortex Hormones. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07337772 currently recruiting?
Yes, NCT07337772 is actively recruiting participants. Contact the research team at drcfzhang@fjmu.edu.cn for enrollment information.
Where is the NCT07337772 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07337772 clinical trial?
NCT07337772 is sponsored by First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 120 participants.